

The Guatemalan Liver Association, that can shorten AGH, is a private entity, non-profit, apolitical, non-religious, with medical-social character, dedicated to fight against diseases and disorders of the liver, gallbladder and biliary tract, through prevention or control activities.
It is formed by people interested in the solution of these conditions, including among its members health professionals, affected individuals and families, as well as anyone seeking the achievement of the aims of this Association.
Goals and Objectives :
1. Inform the public about the importance of the liver for life, and on the measures of prevention of diseases afflicting it.
2. Promote access to preventive measures for liver diseases.
3. To improve the quality of life of those suffering from liver diseases through:
• Inform and train health professionals on aspects of diagnosis, management and prevention of liver diseases.
• Support health services for the formulation and/or updating of guidelines for the management of liver diseases.
• Promote access to diagnosis and treatment of liver diseases.
• Inform patients and their families about the nature of these diseases.
• Encourage and support the patient´s groups and relatives to share experiences, and provide emotional support.
• Support and/or to carry out research on diseases of the liver.
Activities :
Prevention
Information
Support to patients and relatives
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close